Twist Bioscience Surges as Lilly AI Deal Fuels Bullish Targets
Twist Bioscience (TWST) shares rose 7.38% after announcing a partnership with Lilly for AI-driven drug discovery. Analysts raised price targets to $190–215, citing Twist's role in synthetic biology and AI. The company reported $376.6M revenue, 52% gross margin, and negative EBIT margin of -31.8%. It has a strong balance sheet with $166.8M cash and a current ratio of 2.7. The stock is trading at 23.9x sales and 23x book.
How this was made
The 30-second read
Why it matters
The article recaps a price surge tied to partnership news, offering limited new actionable insight.
Market read
Short‑term bullish bias for TWST; broader sector impact modest.
What to watch
Negative EBIT margin and cash burn suggest financial risk despite AI hype.
Background
Twist Bioscience is a synthetic‑biology company with high growth but negative profitability; recent AI collaborations are being marketed as growth catalysts.
Ticker impact
Twist Bioscience shares jumped 7.38% after news of a Lilly AI partnership and Anthropic AI protein‑design work, driving analyst target hikes.
likely upward pressure as traders price in AI partnership benefits
The article highlights a fresh partnership and analyst target raises, but the move is already reflected in price; no new quantitative data.
Market effects
AI‑enabled biotech may attract more capital to synthetic biology sector.
US biotech investors could see modest reallocation toward AI‑driven firms.
Limited; primarily affects niche biotech/AI crossover space.
Counterpoint
The partnership may not translate into near‑term revenue; high valuation multiples could limit upside.
Key entities
- companyTwist Bioscience Corporation
Synthetic biology firm (NASDAQ: TWST) reporting a 7.38% price rise.
- companyEli Lilly
Pharma partner in AI protein‑design collaboration.
- companyAnthropic
AI firm co‑working on protein‑design with Twist.
